Edit Business Wire
20 Aug 2013
DUBLIN--(BUSINESS WIRE)--Research and Markets (http.//www.researchandmarkets.com/research/qkz9rf/ovarian_cancer) has announced the addition of the "Ovarian Cancer Pipeline Analysis" report to their offering. This research report covers all the ongoing drug development in various phases. Each drug profile includes detailed information like ... - Drug Profile Overview . - Active Indication . - Phase of Development ... - Drug Class ... - ATC Codes ....(size: 4.9Kb)
Edit Business Wire
20 Aug 2013
The report gives a comprehensive insight into the various drug profiles being developed for the treatment of Hepatitis C ... Drug Profile Overview Active Indication Phase of Development Country for Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class Patent Information Molecular Formula Pharmodynamics Pharmacokinetics Brand Names Development Agreements ATC Codes . Reasons To Buy ... Key Topics Covered . 1 ... ....(size: 5.4Kb)
Edit Business Wire
20 Aug 2013
DUBLIN--(BUSINESS WIRE)--Research and Markets (http.//www.researchandmarkets.com/research/p262bk/malaria_disease) has announced the addition of the "Malaria Disease Drug Pipeline Analysis" report to their offering. Malaria Disease Drug Pipeline Analysis gives a comprehensive insight into the various drug profiles being developed for the treatment of Malaria ... Each drug profile includes detailed information like ... ... - ATC Codes ... 1 ... 2 ... 3 ... 4 ... 5....(size: 5.1Kb)
Edit Business Wire
20 Aug 2013
"Pancreatic Cancer Drug Pipeline Analysis gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer ... Drug Profile Overview Active Indication Phase of Development Country for Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class Patent Information Molecular Formula Pharmodynamics Pharmacokinetics Brand Names Development Agreements ATC Codes ... 1 ... 2 ... ....(size: 5.7Kb)
Edit Business Wire
20 Aug 2013
DUBLIN--(BUSINESS WIRE)--Research and Markets (http.//www.researchandmarkets.com/research/gm2wtg/europe_orphan) has announced the addition of the "Europe Orphan Drugs Pipeline Analysis" report to their offering. This Europe Orphan Drugs Pipeline Analysis report gives a comprehensive insight into the various drug profiles under the Orphan Drugs status in Europe ... Each drug profile includes detailed information like ... ... - ATC Codes ... 1 ... 2 ... 3 ... ....(size: 5.3Kb)
Edit Seeking Alpha
08 Aug 2013
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd (NYSE ... Rob Koremans, President and CEO of Teva Specialty Medicines ... Dr ... Lonquex® (lipegfilgrastim) is a glycoPEGylated, long-acting form of recombinant human filgrastim, classified with a distinct ATC* code, with a sustained duration of action due to decreased renal clearance ... *ATC. Anatomical Therapeutic Chemical (ATC) Classification System ... About Teva ... (NYSE ... 1 ... 2 ... Eur J Cancer....(size: 13.0Kb)
Edit noodls
08 Aug 2013
(Source. Teva Pharmaceutical Industries Ltd). JERUSALEM--(BUSINESS WIRE)--Aug. 8, 2013-- Teva Pharmaceutical Industries Ltd (NYSE ... Dr ... Product Information about Lonquex® ... Lonquex® (lipegfilgrastim) is a glycoPEGylated, long-acting form of recombinant human filgrastim, classified with a distinct ATC* code, with a sustained duration of action due to decreased renal clearance ... *ATC. Anatomical Therapeutic Chemical (ATC) Classification System ... 1....(size: 13.4Kb)
Edit PR Newswire
18 Mar 2013
Introduction ... The registration includes all active ingredients and excipients as well as their manufacturers, any varying local substance names, the packaging sizes, quantities, MedDRA codes, ATC codes, administration routes, and the current SPC in the local language. In response to this new standard, LORENZ has developed drugTrack™ EVMPD, an e-submissions solution specifically tailored to the new EMA requirements ... RELATED LINKS ... ....(size: 4.7Kb)
Edit StreetInsider
16 Nov 2012
Tweet. Get Alerts SNY Hot Sheet. Price. $42.73 -0.67%. Overall Analyst Rating..     BUY ( Up) ... The applicant for this medicinal product is Sanofi-Aventis (NYSE. SNY) ... The active substance of Zaltrap is aflibercept, an antineoplastic agent (ATC Code not yet assigned) acting as a decoy receptor of Vascular Endothelial Growth Factor (VEGF) thereby blocking the VEGF biological pathway ... The approved indication is ... ....(size: 3.3Kb)
Edit PR Newswire
14 Nov 2012
  Google. , Nov. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Market and Product Forecasts. Melanoma – Yervoy will continue to dominate as new approvals struggle to compete ... Over the forecast period, the value of this market will increase to $1.6bn, demonstrating a CAGR of 10.04% ... Summary of therapeutic classes in melanoma by ATC code, 2012•Table ... US ... ....(size: 12.5Kb)
Edit Business Wire
09 Nov 2012
DUBLIN--(BUSINESS WIRE)--Research and Markets (http.//www.researchandmarkets.com/research/42xh5s/china) has announced the addition of the "China Prescription Drug - Blood Drug Sales Report 2012" report to their offering. “China Prescription Drug - Blood Drug Sales Report 2012” ... This CPD report provides data for the Chinese Blood Products Drug Market, including. ... ... ... - Therapeutic areas categorized using WHO ATC codes ... - B ... U.S....(size: 4.8Kb)
Edit PR Newswire
20 Sep 2011
 . , Sept. 20, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue.. Market and Product Forecasts. Disease Modification in Rheumatoid ArthritisNovel therapies plus reformulations poised to enter the market ... OVERVIEW. •Catalyst. •Summary. EXECUTIVE SUMMARY ... •Related reports ... -. -. - ... Summary of therapeutic classes in rheumatoid arthritis, by ATC code, 2011 ... ....(size: 22.1Kb)